Description: Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 3.2% in the afternoon session after TD Cowen maintained a 'Buy' rating on the stock and increased its price target. The firm's analyst, Marc Frahm, lifted the price target from $101.00 to $128.00, a significant increase of nearly 27%. This adjustment signaled a strong positive outlook for the company's future stock performance. The action from the analyst suggested a heightened confidence in the biopharmaceutical company

Description: If you are wondering whether Incyte's share price still offers value after its recent run, you are not alone. The stock closed at US$103.43 recently, with a 3% decline over the last 7 days, an 8.4% gain over 30 days, 2.0% year to date, 43.8% over 1 year and 10.1% over 5 years. This performance has many investors reassessing both opportunity and risk. Recent coverage has focused on how Incyte fits into the broader pharmaceuticals and biotech space, including ongoing interest in its product...

Description: Incyte is scheduled to release its fourth-quarter results soon, with analysts projecting double-digit surge in its bottom line figure.

Description: Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Description: Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Description: Medicine remains one of the most potentially rewarding of all investment areas. And this biotech stock is flirting with a buy point as analysts see earnings skyrocketing.

Description: Eli Lilly has solidified itself as a global pharma titan. With leading drugs and a massive obesity market, Lilly is poised to be a juggernaut for years to come.

Description: Incyte recently reported positive topline results from its pivotal Phase 3 frontMIND trial, where adding tafasitamab (Monjuvi/Minjuvi) and lenalidomide to R-CHOP improved progression-free survival for newly diagnosed high-risk diffuse large B-cell lymphoma patients without new safety issues. This strengthens the case for tafasitamab as a potential first-line option in a major lymphoma indication, pending planned regulatory filings in 2026. We’ll now examine how the successful frontMIND Phase...

Description: Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.

Description: WILMINGTON, Del., January 05, 2026--Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for DLBCL

Description: Palantir, Nvidia and Intuitive Surgical are among stocks to watch setting up as the market gets ready to close out 2025.

Description: If you are wondering whether Incyte at around $100 a share is still good value or if the easy gains are behind it, you are not alone. This is exactly the question we are going to unpack. The stock is up 44.8% year to date and 44.2% over the last year, even after a modest 1.3% pullback over the past month following a 2.1% rise in the most recent week. This suggests that the market is rapidly rethinking its growth and risk profile. That shift has been driven by a stream of positive pipeline...

Description: In recent days, Incyte announced that the European Commission and Japan’s Ministry of Health, Labour and Welfare approved Minjuvi (tafasitamab) and Zynyz (retifanlimab) in new combination regimens for relapsed or refractory follicular lymphoma and advanced squamous cell carcinoma of the anal canal, expanding treatment options across major oncology markets. These approvals meaningfully broaden Incyte’s oncology footprint in Europe and Japan while deepening its presence in chemotherapy-free...

Description: Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Description: TOKYO, December 22, 2025--Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma

Description: TOKYO, December 22, 2025--Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer

Description: The Standard & Poor's 500 index edged up 0.1% this week as gains led by the consumer discretionary s

Description: Incyte (INCY) has been quietly outperforming the broader biotech space this year, with the stock up about 46% over the past year and more than 40% year to date, drawing fresh attention. See our latest analysis for Incyte. That move has been driven largely by renewed confidence in Incyte’s pipeline and steady revenue growth, with a robust year to date share price return helping to lift its one year total shareholder return and signal building momentum rather than a one off spike. If this kind...

Description: INCY wins EC approval expanding Minjuvi's label, adding a new indication for relapsed or refractory follicular lymphoma after prior therapy.

Description: WILMINGTON, Del., December 18, 2025--Incyte (Nasdaq:INCY) announced today that it will present at the 44th Annual J. P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 am (PST).

Description: WILMINGTON, Del., December 17, 2025--Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Description: Despite Incyte’s outperformance relative to the Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Description: WILMINGTON, Del., December 12, 2025--Incyte Announces Change to its Board of Directors

Description: If you are wondering whether Incyte at around $96.70 is still a smart buy after its big run, you are in the right place to dig into what the market might be getting right or wrong about its value. Despite being down 5.2% over the last week and 8.8% over the last month, the stock is still up 39.1% year to date and 34.1% over the past year, which tells you sentiment has shifted meaningfully in its favor. Recent headlines around Incyte have focused on its expanding dermatology and oncology...

Description: Incyte recently reported encouraging Phase 1 data for its mutant-CALR antibody INCA033989 in myeloproliferative neoplasms and received a U.S. FDA Breakthrough Therapy designation for essential thrombocythemia, while also naming experienced life sciences lawyer Richard Hoffman as Executive Vice President and General Counsel to lead its legal and compliance functions. Together, the promising early data, expedited regulatory status and leadership change highlight how Incyte is pairing pipeline...

Description: WILMINGTON, Del., December 08, 2025--Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in ET

Description: INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.

Description: The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock fell from near five-year highs.

Description: The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock is basing near five-year highs.

Description: WILMINGTON, Del., December 07, 2025--Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with MF Presented at ASH 2025

Description: WILMINGTON, Del., December 07, 2025--Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

Description: WILMINGTON, Del., December 03, 2025--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Description: The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Description: WILMINGTON, Del., December 02, 2025--Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding

Description: Incyte (INCY) shares have shown solid momentum over the past month, gaining 12% and delivering a 21% return over the past 3 months. The company continues to draw investor attention for its performance and pipeline developments. See our latest analysis for Incyte. Incyte’s 50% year-to-date share price return is hard to ignore, reflecting renewed optimism around its clinical pipeline and steady progress in commercial expansion. Despite a slight pullback this week, momentum has built throughout...

Description: WILMINGTON, Del., December 01, 2025--Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel

Description: Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Description: A number of stocks jumped in the afternoon session after a report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies.

Description: Thinking about whether Incyte might be worth more than its current price tag? You are not alone, as many investors are asking the same question right now. The stock has surged 46.8% year-to-date, climbing 42.3% over the past 12 months, despite taking a minor 2.0% dip in the last week. Recent headlines have centered on Incyte’s expanding drug pipeline and positive updates around new FDA approvals, fueling optimism and catching the attention of analysts and shareholders. These developments are...

Description: When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Description: WILMINGTON, Del., November 19, 2025--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of December:

Description: MORGES, Switzerland, November 17, 2025--Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)

Description: Incyte has delivered better returns than the broader market over the past year, and analysts view the stock’s outlook with measured optimism.

Description: Incyte (INCY) has delivered a steady performance lately, as investors track the company’s moderate growth trends and recent market movements. Over the past month, shares have climbed 28%, indicating renewed attention from the market. See our latest analysis for Incyte. After surging nearly 28% over the past month, Incyte’s share price is showing real momentum as investors absorb recent developments and weigh the company’s moderate but persistent growth. In fact, the company’s 55.7%...

Description: Ocular Therapeutix stock is one stock that just reached the mark, now earning a score of 81. Is Ocular Therapeutix Stock A Buy? Ocular Therapeutix stock is currently trading below its 50-day moving average, but rallying with the sector.

Description: A Relative Strength Rating upgrade for Halozyme Therapeutics shows improving technical performance. Will it continue?

Description: Wondering whether Incyte is priced right, or if the market is missing something? You're not alone. This is one biotech that has investors talking about value. The stock has surged 17.2% in just the past week, racking up a 52.0% gain year-to-date and rising 30.6% over the last twelve months. This has prompted many to reconsider its growth potential and risk profile. Much of this momentum came on the heels of positive headlines around recent product pipeline updates and strategic partnerships...

Description: WILMINGTON, Del., November 06, 2025--Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema

Description: Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised Cumulative capital expected to fund planned operations into 2027 based on the Company’s preliminary estimates, and potentially int

Description: Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) Prelude to receive a $35 million upfront payment and $25 million strategic equity investment, $100 million if Incyte were to exercise the option to acquire the program, and up to $775 million in additional potential milestones plus royalties on net sa

Description: We recently published Wall Street Can’t Keep up With These 10 Crushing Stocks; 6 at Fresh Record Highs. Incyte Corp. (NASDAQ:INCY) is one of the best-performing on Monday. Incyte extended its winning streak to a third straight day to hit a new all-time high as investors took heart from an investment firm’s bullish coverage for […]

Description: The Morning Bull - US Market Morning Update Tuesday, Nov, 4 2025 US stock futures are sliding premarket as investors digest hawkish signals from the Federal Reserve and ongoing signs of strain in the manufacturing sector. With Fed officials making it clear that a December rate cut is not guaranteed, and manufacturing data painting a mixed, uncertain picture, market sentiment is becoming more cautious as investors weigh the impact of elevated yields and weaker production on broader economic...

Description: Incyte’s third quarter saw revenue and profit surpass Wall Street’s expectations, yet the market responded negatively. Management identified robust demand for key drugs Jakafi and Opzelura, alongside the launch traction of Niktimvo, as major contributors to the quarter’s strong operational performance. CEO William Meury emphasized the company’s ongoing cost discipline and strategic investment in core R&D programs. He noted, “Our job right now is to keep [the fundamentals] that way and to identif

Description: WILMINGTON, Del., November 03, 2025--Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting

Description: Incyte Corp (INCY) reports a 20% revenue increase, raises full-year guidance, and outlines strategic shifts amid competitive challenges.

Description: The United States vitiligo market is projected to grow from $202.87 million in 2024 to $320.71 million by 2033, driven by a 5.22% CAGR from 2025. This growth is fueled by increasing awareness, innovative therapies, and improved diagnostic methods. Key treatment advancements include biologics, phototherapy, and topical solutions. Challenges include limited curative options and high treatment costs. States like California, New York, Texas, and Florida lead due to strong healthcare infrastructure.

Description: WILMINGTON, Del., October 30, 2025--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November:

Description: Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share was 38% above analysts’ consensus estimates.

Description: Incyte Corporation recently reported third-quarter 2025 earnings well above analyst expectations, with revenue rising to US$1.37 billion and net income reaching US$424.17 million, while also presenting strong late-stage clinical trial results for key immunology and oncology assets. These developments highlight both robust demand for Incyte's current products and growing investor confidence in the company's pipeline, particularly as it prepares for new product launches and international...

Description: Incyte stock edged down Tuesday despite widely beating third-quarter forecasts, on its light 2025 outlook.

Description: This biotech under $100 looks like a growth opportunity worth grabbing before it soars.

Description: Incyte Corporation (NASDAQ:INCY) is one of the most profitable biotech stocks to buy. Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Incyte Corporation (NASDAQ:INCY) on October 22, setting a price target of $104. However, J.P. Morgan analyst Jessica Fye reiterated a Hold rating on Incyte Corporation (NASDAQ:INCY) on October 20. Fye […]

Description: Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 4.2% in the morning session after the company reported underwhelming third-quarter 2025 financial results.

Description: Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.

Description: William Meury: Thank you, Alexis, and good morning, everyone. In terms of the core business, my assessment has reinforced my confidence in the growth potential of our key products. The fundamentals around Jakafi, Opzelura, and our hematology business, Naktinvo and Monjuvi, namely, remain strong.

Description: While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: Incyte (INCY) delivered earnings and revenue surprises of +36.14% and +8.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share was 38% above analysts’ consensus estimates.

Description: WILMINGTON, Del. AP) — Incyte Corp. INCY) on Tuesday reported third-quarter earnings of $424.2 million.

Description: WILMINGTON, Del., October 28, 2025--Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates

Description: ANIP's rising Cortrophin Gel sales and new rare disease products, along with generic and other segments, could power another earnings beat this quarter.

Description: WILMINGTON, Del. & CINCINNATI, October 27, 2025--Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System

Description: Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings this Tuesday morning. Here’s what you need to know.

Description: New data from the Phase 3 BRAVE-AA-PEDS trial highlights baricitinib’s strong performance in adolescents facing severe alopecia areata. Incyte (INCY) and Eli Lilly now plan to pursue global approvals for expanded use based on these results. See our latest analysis for Incyte. Incyte’s momentum has really picked up this year thanks to positive trial results and recent pipeline updates, such as its advances in atopic dermatitis and cancer immunotherapies. The stock’s strong 31% share price...

Description: WILMINGTON, Del., October 25, 2025--Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis

Description: INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.

Description: Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Description: New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. These 52-week results from the BRAVE-AA-PEDS trial – the largest Phase 3 study of its kind – will be presented at the 2025 Fall Clinical Dermatology (FCD) Conference, taking place Oct. 23-26 in Las Vegas.1

Description: Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Incyte will release its third-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

Description: If you've been thinking about what to do with your Incyte shares, or whether now is a smart time to jump in, you’re not alone. The stock has been on the move lately, catching the attention of both careful investors and opportunists alike. In the past week alone, Incyte has climbed 3.4%, adding to a year-to-date rise of 25.9%. Over the last year, shareholders have enjoyed a 34.2% return, a marked turnaround from its rather sluggish five-year performance, which is still down 3.2%. That kind of...

Description: Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Description: WILMINGTON, Del., October 19, 2025--Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced CRC and KRAS G12D Inhibitor in Advanced PDAC